Company Description
Virax Biolabs Group Limited, a biotechnology company, focuses on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated diseases in the United Kingdom, the United States, and China.
The company offers ViraxImmune, a T cell-based immune profiling and diagnostic platform for post-acute infection syndromes, including long COVID, myalgic encephalomyelitis / chronic fatigue syndrome, and post-treatment Lyme disease.
It also provides ImmuneSelect, a research-use-only portfolio of peptide pool ELISpot plates and related immune reagents.
In addition, the company is involved in research and development activities and the provision of procurement, warehousing, product development, and staffing management services.
It serves research organizations, academic institutions, contract research organizations, biopharmaceutical companies, independent laboratories, and distributors.
The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021.
Virax Biolabs Group Limited was founded in 2013 and is headquartered in Lanarkshire, United Kingdom.
| Country | United Kingdom |
| Founded | 2013 |
| IPO Date | Jul 21, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 26 |
| CEO | James Foster |
Contact Details
Address: BioCity Glasgow, Bo’Ness Road Newhouse Lanarkshire, ML1 5UH United Kingdom | |
| Phone | 44 20 7788 7414 |
| Website | viraxbiolabs.com |
Stock Details
| Ticker Symbol | VRAX |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 1885827 |
| CUSIP Number | G9495L133 |
| ISIN Number | KYG9495L1335 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| James Foster | Chairman, Chief Executive Officer and Principal Accounting Officer |
| Dr. Nigel McCracken M.Sc., Ph.D. | Chief Operating Officer and Director |
| Clement Monteil | Head of Scientific Research and Development |
| Lily Fu | Head of Supply Chain |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 24, 2026 | F-3 | Filing |
| Jul 16, 2026 | 6-K | Report of foreign issuer |
| Jul 10, 2026 | 6-K | Report of foreign issuer |
| Jul 9, 2026 | 6-K | Report of foreign issuer |
| Jul 6, 2026 | 20-F | Annual and transition report of foreign private issuers |
| Jun 24, 2026 | 6-K | Report of foreign issuer |
| Jun 12, 2026 | 6-K | Report of foreign issuer |
| May 26, 2026 | 6-K | Report of foreign issuer |
| May 22, 2026 | 6-K | Report of foreign issuer |
| May 15, 2026 | SCHEDULE 13G/A | Filing |